PVT1 and gastric cancer: Analyses showed that, in patients with high PVT1 expression, the addition of 5-Fu based adjuvant did not improve the FPS (Figure 2(e)) and OS (Figure 2(f)) of GC patients; however, the adjuvant without 5-Fu improved the FPS (Figure 2(g)) and OS (Figure 2(h)) of GC patients significantly.